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Abstract:
Background - Type 2 diabetes (T2D) and cardiovascular disease (CVD) share risk factors and 
subclinical atherosclerosis (SCA) predicts events in those with and without diabetes. T2D 
genetic risk may predict both T2D and SCA. We hypothesized that greater T2D genetic risk is 
associated with higher extent of SCA.  
Methods and Results - In a cross-sectional analysis including up to 9,210 European Americans, 
3,773 African Americans, 1,446 Hispanic Americans and 773 Chinese Americans without 
known CVD and enrolled in the FHS, CARDIA, MESA and GENOA studies, we tested a 62
T2D-loci genetic risk score (GRS62) for association with measures of SCA, including coronary 
artery (CACS) or abdominal aortic calcium score, common (CCA-IMT) and internal carotid 
artery intima-media thickness, and ankle-brachial index (ABI). We used ancestry-stratified linear 
regression models, with random effects accounting for family relatedness when appropriate, 
applying a genetic-only (adjusted for sex) and a full SCA risk factors adjusted model 
(significance = p<0.01 = 0.05/5, number of traits analyzed). An inverse association with CACS 
in MESA Europeans (fully-adjusted p=0.004) and with CCA-IMT in FHS (p=0.009) was not 
confirmed in other study cohorts, either separately or in meta-analysis. Secondary analyses 
showed no consistent associations with ?-cell and insulin resistance sub-GRS in FHS and 
CARDIA. 
Conclusions - SCA does not have a major genetic component linked to a burden of 62 T2D loci 
identified by large genome-wide association studies. A shared T2D-SCA genetic basis, if any, 
might become apparent from better functional information about both T2D and CVD risk loci. 
Keywords: genetic association, risk assessment, subclinical atherosclerosis risk factor, type 2 
diabetes mellitus, cardiovascular disease
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Introduction
Type 2 diabetes (T2D) and cardiovascular disease (CVD) are clinically associated in adults1 and 
are an increasing public health and economic scourge in the US2, 3 and worldwide4, 5. Better 
prevention strategies require comprehension of risk factors and mediators underlying T2D and 
CVD6. T2D and CVD share a common metabolic milieu that triggers metabolic and vascular 
dysfunction starting at subclinical disease stages7 due to genetic and non-genetic risk factors. In 
particular, many recently identified common genetic variants increasing T2D risk also are 
associated with increased CVD risk8, 9 and so might confer risk for subclinical atherosclerosis 
(SCA)10.  
 Recently, a set of 36 single nucleotide polymorphisms (SNPs) previously identified in 
large genome-wide association studies (GWAS) as affecting T2D risk were associated with an 
increased risk of cardiovascular complications in T2D patients8. We have also shown that an 
additive genetic risk score (GRS62) comprised of 62 validated T2D-associated SNPs11-14 predicts 
incident T2D in European and African Americans15, 16. 
 The present work sought to investigate whether the T2D genetic burden, as represented 
by the polygenic T2D GRS62, is associated in cross-sectional analyses with variation in SCA 
measures, including coronary artery (CACS) or abdominal aortic calcium score (AACS), internal 
(ICA-IMT) or common carotid artery intima-media thickness (CCA-IMT), and ankle-brachial 
index (ABI).  
To maximize our sample size we conducted a multicenter transethnic association study in 
large population samples from four studies currently ongoing across the US: the Framingham 
Heart Study (FHS), the Coronary Artery Risk Development in Young Adults (CARDIA)17, the 
Multi-Ethnic Study of Atherosclerosis (MESA)18, 19 and the Genetic Epidemiology Network of 
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Arteriopathy (GENOA)20, 21. 
Methods
1. Population  
The Offspring Cohort of the Framingham Heart Study 
Analyses were conducted for each measured SCA trait on a range of 1,111 up to 2,822 
participants of European ancestry from the Offspring Cohort of the FHS22. These subjects 
pertained the same cohort used to validate the predictability of incident T2D by GRS6219.
Outcomes of interest and clinical characteristics were obtained at Offspring examination cycles 6 
(for analyses of ICA-IMT and CCA-IMT) and 7 (for CACS and AACS). ABI was measured 
between the two examinations and covariates included in ABI analyses were from the closest 
examination to ABI evaluation date. More details have been published previously22, 23.  
The CARDIA Study
Analyses were conducted for the available SCA traits on 816 African Americans and 1,635 
European Americans17. Only participants with complete genotype and clinical information for all 
predictors of interest were included in the analyses. We used data on SCA from follow-up visit at
years 20 (ICA-IMT and CCA-IMT) and 25 (CACS). 
The MESA Study
The MESA Study was designed to prospectively evaluate the development and progression of 
atherosclerotic disease19. The selection included individuals from the resident list of adults from 
the urban areas of the recruiting centers with emphasis on ethnic diversity. The present study 
included up to 2,526 participants of European ancestry, 1,611 African Americans, 773 Asian 
Americans and 1,446 Hispanic Americans from examination year 1 (2000-2001). 
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The GENOA Study
The longitudinal Genetic Epidemiology Network of Arteriopathy (GENOA) Study is one of four 
networks in the NHLBI Family-Blood Pressure Program and aims to elucidate the genetics of 
target organ complications of hypertension21. GENOA recruited European and African American 
sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 
years. European Americans were recruited from the Rochester, MN Field Center and African 
Americans were recruited from the Jackson, MS Field Center. Current analyses were conducted 
on CACS measures and genotypes available for 969 European Americans and 535 African 
Americans. 
 In all study cohorts, participants with a personal history of CVD defined as myocardial 
infarction, stroke, coronary angioplasty and/or amputation not due to injury, when applicable, 
were excluded from the analyses.
2. Assessment of subclinical atherosclerosis 
SCA measures were determined in a similar fashion in all studies by carotid ultrasonography 
intima-media thickness, subcategorized for common and internal carotid (CCA-IMT, ICA-IMT), 
computed tomography scan for CACS and AACS, and ABI for peripheral artery disease22, 24-27.
All five SCA traits were measured in FHS and MESA participants. ICA-IMT, CCA-IMT28 and 
CACS29 measurements were available in CARDIA. Evaluation and interpretation of CACS 
measures in MESA were conducted as published elsewhere29, 30. In GENOA, CACS was 
measured in European Americans with an Imatron C-150 electron beam CT scanner (Imatron 
Inc., South San Francisco, CA)31. In GENOA African Americans, CACS was measured with 
standard scanning protocols developed as part of the NHLBI’s MESA and CARDIA studies29.
DOI: 10.1161/CIRCGENETICS.114.000740
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3. Genotyping 
Genotyping in FHS was conducted using the Affymetrix GeneChip Human Mapping 500K 
Array supplemented with the Affymetrix 50K array. CARDIA and MESA Studies used the 
Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, California)32. GENOA Study 
used the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, 2007) or the Illumina 
Human 1M-Duo BeadChip (Illumina, 2010) at the Mayo Clinic, Rochester, MN. Quality control 
and imputation for missing genotypes were previously detailed16, 32-34 for FHS and CARDIA. 
Complete information on genotyping and imputation quality of MESA and GENOA are 
available in the Supplementary Material. 
Ethics Statement
Local Institutional Review Boards approved FHS, CARDIA, MESA and GENOA study 
protocols and all participants provided written informed consent.
Statistical Analysis 
The GRS in FHS and CARDIA European Americans was calculated by summing the number of 
risk alleles (0, 1, or 2) at each locus, weighted by its published effect-size (natural log-
transformed)11. For CARDIA African Americans and for each MESA and GENOA ethnic group 
we used an unweighted GRS, calculated by summing the risk alleles across the loci. We used an 
unweighted GRS for non-European ancestry cohorts because most of the T2D SNPs come from 
GWAS conducted among people of European ancestry. However, weighting has little effect on 
the GRS35, makes models fit slightly better, but does not change the ranking of individuals from 
low to high risk15, 35.  
ICA-IMT, CCA-IMT, AACS, CACS, fasting insulin, triglycerides and HDL-cholesterol
were log-transformed to reduce skewness. Descriptive data were expressed as mean±SE, if not 
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otherwise indicated. We used multivariable linear regression models for CARDIA and MESA 
cohorts and similar models in FHS and GENOA with a random effect accounting for family 
relatedness to test the association of an additive 62 T2D SNPs GRS (Supplemental Table 1) with 
measures of SCA.
For each SCA trait we applied models adjusted for sex (genetic-only model) and for a 
comprehensive set of SCA risk factors (full model), as shown in Supplemental Table 2. Principal 
components were included in GENOA and MESA models to control for population stratification 
in each ethnic group. The fully-adjusted model included: sex, age, waist circumference, body 
mass index (BMI), triglycerides, HDL-cholesterol, LDL-cholesterol, fasting insulin, fasting 
glucose, systolic blood pressure (SBP), hypertension/diabetes and/or lipid medication, physical 
activity, smoking, family history of T2D and/or CVD. SBP was excluded in the analysis for ABI 
since ABI is calculated from SBPs at ankle and arm.
 We also conducted subsidiary analyses of two subsets of the 62 T2D SNPs comprised of 
20 tag-SNPs thought to be associated with ?-cell function (GRS?) or 10 associated with insulin 
resistance (GRSIR)16 in the FHS and CARDIA cohorts to further elucidate possible mechanistic 
pathways, testing the hypothesis that genetic risk for IR in particular would be associated with 
SCA. 
 The rationale behind computing a GRS to account for the cumulative burden of a genetic 
exposure stands upon prior literature36, 37. Indeed, using GRS allows to carry out association 
analyses by treating the genetic exposure as a whole, irrespective of the number of SNPs 
comprised in the score.   
 Post-hoc power calculations using QUANTO 1.2 software showed that for a sample size 
of 1,835 individuals, we had 80% power to detect association of GRS62 explaining 0.64% of the 
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variance in SCA traits with type 1 error rate set at p<0.01 (p=0.05 divided by the number of traits 
(5) analyzed). We had 80% power to detect association of GRS? and GRSIR each explaining 
0.73% or more of the variance in SCA traits with type 1 error set at p<0.005 (0.05/[5 traits x 2 
GRS]). 
In order to replicate the primary FHS analyses in European Americans and to verify 
whether they might be extended to different ancestral groups, we conducted association analyses 
of GRS62 with CACS, ICA-IMT and CCA-IMT in CARDIA, MESA and GENOA cohorts 
separately within each ethnicity. Then, association results from each cohort were meta-analyzed 
using a fixed effect approach, separately for European and African Americans, with a two-sided 
p<0.01 as threshold for significance. 
All statistical analyses were carried out with SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA) and R 2.9.2 (http://www.r-project.org).  
Results
We analyzed up to 7,952 European Americans, 2,124 Africans Americans, 773 Asian Americans 
and 1,446 Hispanic Americans from four cohort studies. Clinical and anthropometric features 
and measures of SCA traits are shown for each study cohort in Supplemental Table 3 and 
Supplemental Table 4.  
Overall, study participants were of a wide age and BMI range. Prevalence of diabetes and 
abdominal obesity was much higher in African Americans than in other ethnicities. Participant 
characteristics within each ethnic group were comparable across all cohorts with the proportion 
of males and females being equally distributed, except in GENOA African Americans where 
women comprised 74.2% of the participants. The T2D GRS62 was approximately normally 
distributed with a range from 48.3 to 83.3 in European Americans and from 46.8 to 83.2 in 
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African Americans over all cohorts. African Americans in CARDIA had higher mean GRS than 
European Americans, while the opposite was the case in MESA and GENOA cohorts. In MESA 
Asian and Hispanic Americans the T2D GRS62 spanned, respectively, from 48.1 to 73.6 and 
from 48.5 to 79.6 (Supplemental Figure 1 and Supplemental Figure 2). GRS? and GRSIR were 
normally distributed and ranged from 12.2 to 31.9 and from 3.3 to 18.0 in FHS and CARDIA 
European Americans, respectively, while in CARDIA African Americans the GRS? ranged from 
13.2 to 28.4 and the GRSIR ranged from 5.0 and 16.9 (Supplemental Figure 2).  
The primary analyses in FHS showed an inverse association between GRS62 and CCA-
IMT (p=0.009, full model), which was not replicated in CARDIA or MESA (Table 1) European 
Americans. In the MESA European Americans, there was a significant inverse association 
between GRS62 and CACS (p=0.004, full model), which was not replicated in other cohorts 
(Table 1). Lack of a significant association between GRS62 and SCA was confirmed by meta-
analyses of up to 12,983 individuals from four cohorts for the available SCA traits, i.e. CACS, 
CCA-IMT and ICA-IMT (Figure 1).
 Supplemental analyses showed that ICA-IMT was negatively associated with GRS? in 
FHS in the full model (p=0.007, Supplemental Table 5), but this finding was not replicated in
CARDIA European Americans. The GRSIR was not associated with any SCA trait in any of the 
models in either the FHS cohort or in either CARDIA ethnic group (Supplemental Table 6). 
Discussion
The primary finding of our study was the absence of a significant association between the 
genetic burden for T2D, based on a 62 SNPs GRS, and a wide set of SCA traits in a large US 
adult population. Results were consistent for all four ancestral groups studied. An inverse 
association of the GRS62 with CCA-IMT in FHS was not confirmed in two other cohorts either in 
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replication comparisons or meta-analysis. A 10 SNP GRS and a 20 SNP GRS representing 
variants associated, respectively, with ?-cell function or insulin resistance also showed no 
significant association with SCA. 
 A wide literature has validated the approach of using a T2D GRS in diverse populations 
as a robust predictor of T2D, whether alone or considering clinical variables16, 17, 35, 38-41. Prior 
studies also used the T2D GRS to predict vascular disease8, 42-44, showing that T2D susceptibility 
variants are able, cumulatively, to predict coronary heart disease (CHD) events. As single genetic 
variants only explain a very small proportion of the variation in T2D risk, we did not expect 
individual SNPs to achieve study-wide significance for association with SCA traits, especially 
with the present sample size. To overcome weak effects of individual variants, we therefore 
applied the widely used strategy of expressing overall T2D genetic risk burden as a GRS, to test 
for association with SCA. Indeed, a recent analysis of the cumulative effect of common genetic 
variation associated with BMI- and fasting insulin loci showed that a higher burden of variants 
was associated with metabolic syndrome traits, IR and CHD events, but not SCA45.  
 Starting with the plausible hypothesis that T2D genetic risk would be associated with 
SCA, we used a rigorous approach including conservative correction for multiple trait tests, 
replication studies in separate cohorts (thereby reducing type 1 error) and meta-analysis of a 
large sample size (increasing power). We therefore can conclusively state that a measure of T2D 
genetic risk is not associated with higher indices of SCA in these cohorts.  
These results can be compared with other recent studies. As recently reviewed9, the 
genetic signatures of T2D, CHD and glycemic quantitative traits seem to overlap only at
chromosomes 2q36.3 and 9p21.3. Notably, a major proportion of fasting insulin-associated loci 
have shown directionally consistent associations with T2D risk and CVD quantitative risk factors 
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(i.e. adverse lipid profile and abdominal adiposity) but none of the glycemic quantitative traits 
has been directly associated with CVD-risk. In this context, Qi et al.8 showed that the genetic 
risk of T2D, as represented by a 36 T2D SNPs GRS, was associated with an increased risk of 
CVD in European Americans affected by T2D. Additionally, while Doria et al.46 showed that the 
effect of genotype at 9p21.3 locus on CVD events was raised only in persons with T2D with
poor glycemic control, Rivera et al.47 found that, compared to non-T2D individuals, the genetic 
variation at 9p21.3 locus was associated with a higher severity of coronary artery disease 
comorbid with T2D. On the other hand, a recent analysis in the FHS22 specifically pointing to the 
genetic variation at candidate 2q36.3-IRS1 locus failed to identify an etiological link between 
SCA and T2D. 
It might therefore be argued that distinct mechanisms lead T2D and non-T2D subjects to 
CVD events, and that within T2D cases hyperglycemia might act as permissive environment 
leading to the full expression of CVD-risk genetics. These data, together with the null results of 
our present study, both with our T2D GRS62 and with the two sub-scores (GRSIR and GRS?), 
collectively suggest that in the general population T2D and CVD are not genetically linked 
together through SCA, the association of T2D genetics being so far observed only with CVD 
events but not with early subclinical disease.
Our analysis plan was designed to specifically test the impact of a comprehensive T2D 
genetic risk burden on SCA risk. We therefore created a basic, purely genetic, model by 
including as exposure both GRS and sex, as sex is 100% genetically determined and is also 
associated with T2D risk. Then, we added covariates like age and other confounders/mediators 
not completely genetically determined but potentially related to a pro-atherosclerotic, pro-
diabetic phenotype. In particular, we did not specifically aim to mechanistically unravel the 
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pathobiology of atherosclerosis. Instead, we adjusted for sex in the genetic-only model to simply 
address the question of whether the known spectrum of established genetic determinants of T2D 
(including sex chromosome) is associated with measures of SCA. 
 Strengths of our study include a validated T2D GRS aligned to the current level of 
evidence, a detailed characterization of SCA, a comprehensive selection of covariates, and a
careful control of type 1 and type 2 error by means of a large sample size from the general 
population and a multicenter replication strategy in different ethnicities. Additionally, given the 
strong age-calcification relationship across young adulthood, mid-life and older ages48, 49, the 
wide range of age among our different cohorts allowed to capture the whole spectrum from 
early- to late-onset calcification. 
 However, our approach might have been weakened by multiple interactions among 
different SNPs within the GRS: several of the component genes in the score may be indeed 
associated with SCA, but the component score might not be significantly associated if the effect 
was diluted by the other variants. We did not perform individual SNP tests for association with 
SCA, as individual locus effects were not our main hypothesis and would require a vast sample 
size to account for the increased type 1 error rate and to identify individual locus effects, the 
threshold for significance being in that case p<1.6x10-4 (i.e. 0.05/(5 SCA traits) x (62 SNPs)). 
Furthermore, the 62 genome-wide significant SNPs we used explained only a fraction (around 
10%) of the total T2D phenotypic variance in other studies50 and did not represent actual 
functional variants that have yet to be discovered. We also acknowledge that the exclusion of 
CVD individuals, may have resulted in a population enriched for protective factors especially 
among those with higher T2D GRS, which would explain the borderline negative association of 
the GRS62 with CCA IMT in FHS and CACS in MESA European Americans.  However, in 
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sensitivity analyses conducted in FHS and CARDIA the T2D GRS62 allele distribution was 
comparable between people with positive CVD history and the population actually analyzed
(data not shown). Hence, for consistency with our main focus on SCA we excluded individuals 
with clinical CVD. The relatively younger age of CARDIA participants offers another possible 
limitation, however, it is well known that SCA begins to develop in Westernized populations in 
early youth51, 52. Further, associations in CARDIA were similar to those in the other cohorts we 
studied. Lastly, while we could confidently use the GRS to depict the T2D genetic risk for 
European and Mexican Americans, and therefore reasonably claim robustness of our results, our 
GRS was not best tailored to African or Asian Americans. However, we have shown in several 
prior studies that T2D GRS based on SNPs found in European ancestry samples do predict T2D 
in African American samples, even accounting for clinical risk factors16, 17, 53. 
 Our results have several implications and point to future directions.  We provided 
compelling evidence that the genetic burden of T2D risk as represented by our GRS62
formulation was not associated with SCA. This suggests that T2D and SCA have separate 
genetic structures and that no large common variant genetic soil10 underlies both T2D and CVD.
However, it is possible that more complex formulation of T2D genetic risk might be associated 
with SCA.
T2D and SCA are linked clinically1, 8 and the prevalence of CVD events and the burden 
of CVD risk factors are higher in T2D patients. Furthermore, there is evidence that screening for 
SCA in asymptomatic individuals at intermediate CVD risk improves the predictability of the 
occurrence of CVD over and above established CVD risk factors54. Incorporating genetic 
information into disease prediction models would further improve the ability to capture people 
with higher CVD risk at a preclinical stage. However, current polygenic scores do not 
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remarkably outperform clinical models15 and functional interrogation of T2D and CVD genetics 
is necessary to further optimize polygenic risk prediction of either T2D or CVD or both. 
Therefore, despite our understanding of the genetic signature of complex traits is steadily 
increasing, new approaches incorporating functional, structural and/or regulatory annotation55
into disease prediction are needed to untangle the missing link, if any, between T2D and CVD at 
a genetic level. 
In conclusion, common polygenic T2D risk variation, as incorporated in a comprehensive 
and validated GRS, was not associated with any of five measures of SCA. Our study suggests 
that the biological and genetic relationships among T2D, CVD and SCA are probably more 
complex than expected. Further mechanistic investigations are needed to explore whether shared 
or distinct vascular disease mechanisms related to T2D might be in play. Therefore, given the 
global burden of T2D and CVD in the era of precision medicine and patient-oriented healthcare,
it is timely to achieve a deeper understanding about the genetic determinants of T2D, CVD and 
intermediate risk traits, in order to improve risk prediction and the ability to discover newly 
targeted therapeutic molecules.
Funding Sources: MD was supported by research grants of the University of Verona and 
Massachusetts General Hospital-Harvard Medical School. JLV was supported by U01 
HG006500 and L30 DK089597 from NIH. 
The Framingham Heart Study: This research was conducted in part using data and resources 
from the Framingham Heart Study of the National Heart Lung and Blood Institute of the 
National Institutes of Health and Boston University School of Medicine. The analyses reflect 
intellectual input and resource development from the Framingham Heart Study investigators 
participating in the SNP Health Association Resource (SHARe) project. This work was partially 
supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract 
No. N01-HC-25195). A portion of this research utilized the Linux Cluster for Genetic Analysis 
DOI: 10.1161/CIRCGENETICS.114.000740
16
(LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at 
Boston University School of Medicine and Boston Medical Center. Also supported by National 
Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to JBM, 
NIDDK K24 DK080140 to JBM, and NIDDK Research Career Award K23 DK65978, a 
Massachusetts General Hospital Physician Scientist Development Award and a Doris Duke 
Charitable Foundation Clinical Scientist Development Award to JCF.
The CARDIA Study: The CARDIA Study is conducted and supported by the National Heart, 
Lung, and Blood Institute in collaboration with the University of Alabama at Birmingham 
(HHSN268201300025C & HHSN268201300026C), Northwestern University 
(HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation 
Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine 
(HHSN268200900041C). CARDIA is also partially supported by the Intramural Research 
Program of the National Institute on Aging. This manuscript has been reviewed and approved by 
CARDIA for scientific content.
The MESA Study: MESA and the MESA SHARe project are conducted and supported by the 
National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. 
Support is provided by grants and contracts N01 HC-95159, N01-HC-95160, N01-HC-95161, 
N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-
95167, N01-HC-95168, N01-HC-95169, N02-HL-64278 and RR-024156. Funding for CARe 
genotyping was provided by NHLBI Contract N01-HC-65226. The provision of genotyping data 
was supported in part by the National Center for Advancing Translational Sciences, CTSI grant 
UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease 
Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes 
Endocrinology Research Center. The authors thank the participants of the MESA study, the 
Coordinating Center, MESA investigators, and study staff for their valuable contributions.  A full
list of participating MESA investigators and institutions can be found at http://www.mesa-
nhlbi.org.
The GENOA Study: Genetic Epidemiology Network of Arteriopathy (GENOA) study is 
supported by the National Institutes of Health, grant numbers HL087660 andHL100245 from 
National Heart, Lung, Blood Institute. We thank Eric Boerwinkle, PhD and Megan L. Grove 
from the Human Genetics Center and Institute of Molecular Medicine and Division of 
DOI: 10.1161/CIRCGENETICS.114.000740
17
Epidemiology, University of Texas Health Science Center, Houston, Texas, USA and Julie 
Cunningham, PhD from the Department of Health Sciences Research, Mayo Clinic College of 
Medicine, Rochester, MN, USA for their help with genotyping.
No additional external funding was received for this study. The funders had no role in the design 
or preparation of the manuscript. 
Conflict of Interest Disclosures: The FHS, CARDIA, MESA and GENOA authors have no 
conflict of interest to disclose. JBM serves as consultant to Quest Diagnostics.  
References:
1. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. 
Diabetologia. 2013;56:686-695. 
2. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Diabetes 
Care. 2013;36:1033-1046. 
3. Dabelea D, Saydah S, Imperatore G, Linder B, Divers J, Bell R, et al. Prevalence of Type 1 
and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009. JAMA.
2014;311:1778. 
4. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the 
WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 Suppl 2:S14-
S21. 
5. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the 
prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-321. 
6. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, et al. Prevalence and 
prognostic impact of subclinical cardiovascular disease in individuals with the metabolic 
syndrome and diabetes. Diabetes. 2007;56:1718-1726. 
7. Zhang H, Dellsperger KC and Zhang C. The link between metabolic abnormalities and 
endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol. 2012;107:237. 
8. Qi Q, Meigs JB, Rexrode KM, Hu FB, Qi L. Diabetes genetic predisposition score and 
cardiovascular complications among patients with type 2 diabetes. Diabetes Care. 2013;36:737-
739.
9. Dauriz M, Meigs JB. Current Insights into the Joint Genetic Basis of Type 2 Diabetes and 
Coronary Heart Disease. Curr Cardiovasc Risk Rep. 2014;8:368. 
DOI: 10.1161/CIRCGENETICS.114.000740
18
10. Stern MP. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes.
1995;44:369-374. 
11. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al. Large-
scale association analysis provides insights into the genetic architecture and pathophysiology of 
type 2 diabetes. Nat Genet. 2012;44:981-990. 
12. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 
diabetes susceptibility loci identified through large-scale association analysis. Nat Genet.
2010;42:579-589. 
13. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases 
of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678. 
14. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of 
genome-wide association data and large-scale replication identifies additional susceptibility loci 
for type 2 diabetes. Nat Genet. 2008;40:638-645. 
15. Hivert MF, Vassy JL, Meigs JB. Susceptibility to type 2 diabetes mellitus-from genes to 
prevention. Nature Rev Endocrinol. 2014;10:198-205. 
16. Vassy JL, Hivert MF, Porneala B, Dauriz M, Florez JC, Dupuis J, et al. Polygenic type 2 
diabetes prediction at the limit of common variant detection. Diabetes. 2014;63:2172-2182. 
17. Vassy JL, Durant NH, Kabagambe EK, Carnethon MR, Rasmussen-Torvik LJ, Fornage M, et 
al. A genotype risk score predicts type 2 diabetes from young adulthood: the CARDIA study. 
Diabetologia. 2012;55:2604-2612. 
18. Pletcher MJ, Sibley CT, Pignone M, Vittinghoff E, Greenland P. Interpretation of the 
coronary artery calcium score in combination with conventional cardiovascular risk factors: the 
Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2013;128:1076-1084. 
19. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-
ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881. 
20. Daniels PR, Kardia SL, Hanis CL, Brown CA, Hutchinson R, Boerwinkle E, et al. Familial 
aggregation of hypertension treatment and control in the Genetic Epidemiology Network of 
Arteriopathy (GENOA) study. Am J Med. 2004;116:676-681. 
21. FBPP Investigators. Multi-center genetic study of hypertension: The Family Blood Pressure 
Program (FBPP). Hypertension. 2002;39:3-9. 
22. Lim S, Hong J, Liu CT, Hivert MF, White CC, Murabito JM, et al. Common variants in and 
near IRS1 and subclinical cardiovascular disease in the Framingham Heart Study. 
Atherosclerosis. 2013;229:149-154. 
DOI: 10.1161/CIRCGENETICS.114.000740
19
23. O'Donnell CJ, Cupples LA, D'Agostino RB, Fox CS, Hoffmann U, Hwang SJ, et al. 
Genome-wide association study for subclinical atherosclerosis in major arterial territories in the 
NHLBI's Framingham Heart Study. BMC Med Genet. 2007;8 Suppl 1:S4. 
24. Hoffmann U, Siebert U, Bull-Stewart A, Achenbach S, Ferencik M, Moselewski F, et al. 
Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-
detector computed tomography in a community-based cohort--consequences for progression 
studies. Eur J Radiol. 2006;57:396-402. 
25. Murabito JM, Guo CY, Fox CS, D'Agostino RB. Heritability of the ankle-brachial index: the 
Framingham Offspring study. Am J Epidemiol. 2006;164:963-968. 
26. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery 
intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. 
Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22. 
27. Wong ND, Lopez VA, Allison M, Detrano RC, Blumenthal RS, Folsom AR, et al. 
Abdominal aortic calcium and multi-site atherosclerosis: the Multiethnic Study of 
Atherosclerosis. Atherosclerosis. 2011;214:436-441. 
28. Polak JF, Person SD, Wei GS, Godreau A, Jacobs DR, Jr., Harrington A, et al. Segment-
specific associations of carotid intima-media thickness with cardiovascular risk factors: the 
Coronary Artery Risk Development in Young Adults (CARDIA) study. Stroke. 2010;41:9-15. 
29. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR, et al. Calcified coronary 
artery plaque measurement with cardiac CT in population-based studies: standardized protocol of 
Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in 
Young Adults (CARDIA) study. Radiology. 2005;234:35-43. 
30. McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery 
calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis 
(MESA). Circulation. 2006;113:30-37. 
31. Bielak LF, Sheedy PF, 2nd, Peyser PA. Coronary artery calcification measured at electron-
beam CT: agreement in dual scan runs and change over time. Radiology. 2001;218:224-229. 
32. Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK, et al. Genetic loci 
associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association 
studies from the CHARGE Consortium. PLoS Genet. 2011;7:e1002193. 
33. Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, Benjamin EJ, et al. Genome-wide 
association study of coronary heart disease and its risk factors in 8,090 African Americans: the 
NHLBI CARe Project. PLoS Genet. 2011;7:e1001300. 
34. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure 
of haplotype blocks in the human genome. Science. 2002;296:2225-2229. 
DOI: 10.1161/CIRCGENETICS.114.000740
20
35. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in 
addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208-
2219.
36. Janssens AC, Ioannidis JP, van Duijn CM, Little J, Khoury MJ, Group G. Strengthening the 
reporting of Genetic RIsk Prediction Studies: the GRIPS Statement. PLoS Med.
2011;8:e1000420. 
37. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: methodological 
considerations for future research. Genome Med. 2009;1:20. 
38. de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, et al. 
Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 
diabetes risk single nucleotide polymorphisms. Diabetes Care. 2011;34:121-125. 
39. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk 
factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220-
2232.
40. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated 
genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence 
and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011;60:1340-
1348.
41. Yang J and Zhao J. Cumulative Effect of Common Genetic Variants Predicts Incident Type 2 
Diabetes: A Study of 21,183 Subjects from Three Large Prospective Cohorts. Epidemiology.
2011;1:108. 
42. Pfister R, Barnes D, Luben RN, Khaw KT, Wareham NJ, Langenberg C. Individual and 
cumulative effect of type 2 diabetes genetic susceptibility variants on risk of coronary heart 
disease. Diabetologia. 2011;54:2283-2287. 
43. Sousa AG, Lopes NH, Hueb WA, Krieger JE, Pereira AC. Genetic variants of diabetes risk 
and incident cardiovascular events in chronic coronary artery disease. PLoS One. 2011;6:e16341. 
44. Borglykke A, Grarup N, Sparso T, Linneberg A, Fenger M, Jeppesen J, et al. Genetic variant 
SLC2A2 is associated with risk of cardiovascular disease - assessing the individual and 
cumulative effect of 46 type 2 diabetes related genetic variants. PLoS One. 2012;7:e50418. 
45. Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, et al. Genetic 
evidence for a normal-weight "metabolically obese" phenotype linking insulin resistance, 
hypertension, coronary artery disease, and type 2 diabetes. Diabetes. 2014;63:4369-4377. 
46. Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnstone MT, et al. Interaction between 
poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes.
DOI: 10.1161/CIRCGENETICS.114.000740
21
JAMA. 2008;300:2389-2397. 
47. Rivera NV, Carreras-Torres R, Roncarati R, Viviani-Anselmi C, De Micco F, Mezzelani A, 
et al. Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and 
absence of type 2 diabetes. BMC Med Genet. 2013;14:11. 
48. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, et al. Prevalence and progression 
of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated
risk for cardiovascular disease: the coronary artery risk development in young adults study and 
multi-ethnic study of atherosclerosis. Circulation. 2009;119:382-389. 
49. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, et al. Risk factors
for the progression of coronary artery calcification in asymptomatic subjects: results from the 
Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;115:2722-2730. 
50. Wray NR, Yang J, Hayes BJ, Price AL, Goddard ME, Visscher PM. Pitfalls of predicting 
complex traits from SNPs. Nat Rev Genet. 2013;14:507-515. 
51. McGill HC, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: 
implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. 
Circulation. 2008;117:1216-1227. 
52. McMahan CA, Gidding SS, Viikari JS, Juonala M, Kahonen M, Hutri-Kahonen N, et al. 
Association of Pathobiologic Determinants of Atherosclerosis in Youth risk score and 15-year 
change in risk score with carotid artery intima-media thickness in young adults (from the 
Cardiovascular Risk in Young Finns Study). Am J Cardiol. 2007;100:1124-1129. 
53. Vassy JL, Dasmahapatra P, Meigs JB, Schork NJ, Magnussen CG, Chen W, et al. Genotype 
prediction of adult type 2 diabetes from adolescence in a multiracial population. Pediatrics.
2012;130:e1235-e1242. 
54. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the 
occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review.
Heart. 2012;98:177-184. 
55. ENCODE Project Consortium, Bernstein BE, Birney E, Dunham I, Green ED, et al. An 
integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57-74. 
DOI: 10.1161/CIRCGENETICS.114.000740
22
Table 1: Association between a 62 T2D SNPs genotype risk score (GRS) and prevalent subclinical atherosclerosis measures in linear 
regression models of FHS, CARDIA, GENOA* and MESA cohorts. 
FHS CARDIA GENOA
European American European Americans African Americans European Americans African American*
Basic Model Beta±SE P Beta±SE P Beta±SE P Beta±SE P Beta±SE P 
CACS -0.012±0.026 0.66 0.011±0.010 0.27 -0.007±0.016 0.64 0.003±0.017 0.88 0.025±0.029 0.40
AACS -0.029±0.032 0.36 - - - - - - - -
ICA-IMT -0.008±0.004 0.03 0.000±0.001 0.88 0.000±0.001 0.67 - - - -
CCA-IMT -0.002±0.002 0.21 0.000±0.000 0.94 0.001±0.001 0.08 - - - -
ABI 0.000±0.001 0.72 - - - - - - - - 
Full Model
CACS -0.012±0.028 0.67 0.006±0.010 0.56 -0.018±0.015 0.24 0.001±0.015 0.95 0.041±0.026 0.12
AACS -0.017±0.033 0.61 - - - - - - - - 
ICA-IMT -0.009±0.004 0.02 0.000±0.001 0.63 0.000±0.001 0.72 - - - -
CCA-IMT -0.004±0.002 0.009 0.000±0.000 0.54 0.000±0.001 0.47 - - - -
ABI 0.001±0.001 0.13 - - - - - - - -
MESA
European Americans Asian Americans African Americans Hispanic Americans
Basic Model Beta±SE P Beta±SE P Beta±SE P Beta±SE P 
CACS -0.026±0.010 0.01 -0.027±0.012 0.14 0.019±0.014 0.17 -0.004±0.014 0.76
AACS -0.042±0.023 0.07 -0.022±0.048 0.65 0.003±0.039 0.93 0.029±0.031 0.33
ICA-IMT -0.001±0.002 0.75 0.001±0.004 0.85 -0.001±0.003 0.65 0.006±0.003 0.02
CCA-IMT -0.001±0.001 0.33 -0.001±0.002 0.65 -0.000±0.001 0.79 -8.98E-06±0.001 0.99
ABI 3.27E-05±0.001 0.95 0.000±0.001 0.63 -0.000±0.001 0.64 0.000±0.001 0.61
Full Model
CACS -0.029±0.009 0.004 -0.027±0.019 0.16 0.016±0.014 0.28 0.002±0.015 0.88
AACS -0.012±0.019 0.53 -0.033±0.039 0.40 -0.027±0.035 0.44 0.035±0.028 0.20
ICA-IMT -0.001±0.002 0.63 -0.000±0.004 0.98 -0.002±0.003 0.52 0.006±0.003 0.02
CCA-IMT -0.001±0.001 0.30 -0.001±0.002 0.77 -0.000±0.001 0.87 9.49E-05±0.001 0.93
ABI 0.000±0.001 0.44 0.000±0.001 0.67 -0.001±0.001 0.36 0.000±0.001 0.85
CACS: coronary artery calcium score, AACS: abdominal aorta calcium score, ICA: internal carotid artery, CCA: common carotid artery, IMT: intima-media thickness, ABI: ankle-brachial index. Basic 
Model: SCA trait = GRS + sex + k; Full Model: fully-adjusted model (GRS + sex, age, waist circumference, body mass index, triglycerides, HDL-cholesterol, LDL-cholesterol, fasting insulin, fasting 
glucose, systolic blood pressure (SBP), hypertension/diabetes and/or lipid medication, physical activity, smoking, family history of T2D and/or CVD. SBP was excluded in the analysis for ABI since 
ABI is calculated from SBPs at ankle and arm). *African Americans in GENOA had a genetic risk score limited to 55 of 62 T2D SNPs. Data expressed as mean ± standard error.  Sample sizes (N [min-
max]): FHS NEur [1,111-2,822]; CARDIA: NEur [1,267-1,635], NAfr [562-816]; GENOA: NEur =969, NAfr =535; MESA: NEur [760-2,526], NAsi [247-773]; NAfr [343-1,611], NHis [496-1,446]. 
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Figure Legends:
Figure 1: Meta-analysis of GRS62 association tests with CACS (panel-A, Nmeta=4,780; panel-B, 
Nmeta=1,835), CCA-IMT (panel-C, Nmeta=6,220; panel-D, Nmeta=2,190) and ICA-IMT (panel-E, 
Nmeta=5,842; panel-F, Nmeta=2,109) measures across all study cohorts stratified by European and 
African Americans (GRS62, genetic risk score comprised of 62 single nucleotide polymorphisms 
associated with type 2 diabetes; CACS, coronary artery calcium score; CCA-IMT and ICA-IMT, 
intima-media thickness of common and internal carotid artery). 
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Supplemental*Methods*
We# applied# a# multivariable# linear# regression# model# with# random# effects# to# account# for# family#
relatedness,#where#appropriate,#to#test#the#association#of#subclinical#atherosclerosis#(SCA)#measures#
with#an#additive#genetic#risk#score#(GRS62)#comprised#of#62#single#nucleotide#polymorphisms#(SNPs)#
known#to#be# linked#with# type#2#diabetes# (T2D)# risk# (Table*S1)1.#Many#of# them#are#associated#with#
either#betaJcell#function#or#insulin#resistance#(IR)#physiology.#Therefore,#as#described#by#Vassy#et#al.#
2,#we#used#prior#genetic#and#physiologic#evidence#1,#3J6#to#define#a#subJGRS#comprised#of#20#T2D#SNPs#
mainly#associated#with#betaJcell#function#(GRSβ)#and#a#subJGRS#comprised#of#10#T2D#SNPs#associated#
with#peripheral# insulin# resistance# (GRSIR),#with#each# locus#weighted# in#European#Americans#by# the#
same#effect#size#as#in#the#GRS62.#
For#each#SCA#trait#we#applied#a#geneticJonly#model#(adjusted#for#sex)#and#a#full#atherosclerosis#risk#
factors#adjusted#model# (Table*S2).#Clinical#and#anthropometric#characteristics#of#study#cohorts#are#
shown# in# Table* S3# and# Table* S4.# The# GRSβ# and# GRSIR# were# tested# only# in# FHS# and# CARDIA# study#
samples#(Table*S5?S6).##
Many#of#the#62#tagJSNPs#associated#with#T2D#(Table*S1)#are#also#known#to#be#associated#with#SCA#
risk# factors/confounders.# We# interrogated# Genome.gov# (http://www.genome.gov/),# a# catalog# of#
published# GWAS,# and# PheGenI# (http://www.ncbi.nlm.nih.gov/gap/phegeni),# a# phenotypeJoriented#
resource# housed# at# the# National# Center# for# Biotechnology# Information.# Risk# factors# listed# in# the#
catalogs# as# being# associated# with# one# or# more# of# the# known# 62# T2D# loci# were# included,# among#
others,# in# the# full#model# (BMI,#waist#circumference,# systolic#blood#pressure,# fasting# insulin,# fasting#
glucose,# triglycerides,# HDLJcholesterol# and# LDLJcholesterol).# Therefore,# the# basic# model# could# be#
described#as#“purely”#genetic,#as#it#tested#the#association#of#a#T2D#GRS#alone#with#SCA#traits,#after#
adjustment# for# sex,# while# the# full# model# accounted# for# the# overall# spectrum# of# confounders,#
mediators#and/or#risk#factors#for#SCA#available#in#our#dataset,#by#adjusting#for#a#comprehensive#list#
of#atherosclerosis#risk#factors.#
 2 
Genotyping:#
MESA:# Caucasian,#Hispanic,# and#Chinese#American#participants#were# genotyped#on# the#Affymetrix#
GenomeJWide#Human#SNP#Array#6.0# (Affymetrix,#Santa#Clara,#CA,#USA)#at#the#Affymetrix#Research#
Services#Lab.#6,880#samples#passed#initial#genotyping#QC.#African#American#samples#were#genotyped#
at#the#Broad#Institute#of#Harvard#and#MIT#as#part#of#the#CARe#project#7.#Affymetrix#performed#wet#
lab#hybridization#assay,#and#plateJbased#genotype#calling#using#Birdseed#v2.#Sample#QC#was#based#
on# call# rates# and# contrast# QC# (cQC)# statistics.# Broad# performed# similar# QC# for# CARe# sample.#
Additional#sample#and#SNP#QC#were#carried#out#at#University#of#Virginia,#including#sample#call#rate,#
sample#cQC,#and#sample#heterozygosity#by#ethnicity#at#the#sample# level;#outlier#plates#checking#by#
call#rate,#median#cQC#or#heterozygosity#at#plate#level.# #Four#samples#were#removed#due#to#low#call#
rate# (<95%).#Cryptic# sample#duplicates#or#unresolved#cryptic#duplicates#were#dropped.#Unresolved#
gender#mismatches#were#also#dropped.#At#the#SNP#level,#we#excluded#monomorphic#SNPs#across#all#
samples;# SNPs#with#missing# rate#was#>#5%#or#observed#heterozygosity# ># 53%#were# also#excluded.#
Additional#genotypes#were#imputed#to#the#1000#Genomes#Phase#I#integrated#variant#set#(NCBI#build#
37#/#hg19)#separately#in#each#ethnic#group#using#the#program#IMPUTEv2.#We#used#data#freezes#from#
23# Nov# 2010# (lowJcoverage# wholeJgenome)# and# 21st# May# 2011# (highJcoverage# exome),# phased#
haplotypes# released# March# 2012# (v3),# and# phased# haplotypes# for# 1,092# individuals# and# over# 39#
million# variants.# All# imputed# and# genotyped# SNPs# were# aligned# to# the# '+'# strand# of# the# human#
genome# reference# sequence# (NCBI# Build# 37).# The# Affymetrix# annotation# file#
"GenomeWideSNP_6.na31.annot.csv"#was#used#for#all#matching#of#probe#set#IDs#with#RS#IDs.#
#
GENOA:#GENOA# Study# participants#were# genotyped# on# the# Affymetrix# GenomeJWide#Human# SNP#
Array#6.0#(Affymetrix,#2007)#or#the#Illumina#Human#1MJDuo#BeadChip#(Illumina,#2010)#at#the#Mayo#
Clinic,# Rochester,# MN.# African# American# sibships# for# the# GENOA# study# were# identified# using#
hypertensive#participants# from# the#Atherosclerosis#Risk# in#Communities# Study# (ARIC)# as#probands.#
Genotypes#were#obtained#for#92#additional#GENOA#participants#who#were#also#in#the#ARIC#Study#and#
who#could#not#be#genotyped#on#either#platform#using#the#GENOA#blood#sample.#Genotyping#for#the#
 3 
ARIC# study# was# done# at# the# Broad# Institute# on# the# Affymetrix# 6.0# platform.# For# all# genotyping#
platforms#used,#samples#and#SNPs#with#a#call#rate#<95%#were#removed.#Samples#demonstrating#sex#
mismatch,# duplicate# samples,# and# samples#with# low# identityJbyJstate#with# all# other# samples#were#
also# removed.# Imputation# was# performed# with# the# singleJstep# approach# implemented# in#Markov#
Chain# Haplotyper# (MaCH)# 1.0.16# 8.# The# reference# panel# was# composed# of# the# HapMap# phased#
haplotypes# (release# 22).# Imputation# was# performed# separately# for# participants# genotyped# on# the#
Affymetrix#6.0#as#part#of#the#GENOA#study,#participants#genotyped#on#the#Illumina#Human#1MJDuo#
BeadChip,#and#participants#genotyped#on#the#Affymetrix#6.0#as#part#of#the#ARIC#Study.#Since#only#a#
small#number#of#directly#genotyped#SNPs#overlap#on#the#Affymetrix#and#Illumina#platforms,#imputed#
dosages#were#used#for#all.#
In#GENOA#African#Americans#the#GRS#was# limited#to#55#SNPs#due#to#poor# imputation#quality# for#7#
SNPs.#
#
FHS#and#CARDIA#genotyping#and#imputation#strategy#have#been#previously#detailed#elsewhere2,#7,#9.#
#
#
 4 
 
 
Chr,#chromosome;#SNP,#single#nucleotide#polymorphism;#OR,#odd#ratio##
 
Supplemental*Table*1*–*62*independent*loci*and*relative*tag?SNPs*associated*with*Type*2*Diabetes*from*DIAGRAMv3*1.#*
*
*
Chr* SNP?risk*allele* Locus* OR* Chr* SNP?risk*allele* Locus* OR*
1# rs2075423JG# PROX1#or#PPP2R5A# 1.07# 9# rs10758593JA# GLIS3# 1.06#
1# rs10923931JT# NOTCH2# 1.08# 9# rs17791513JA# TLE4# 1.12#
2# rs10203174JC# THADA# 1.14# 9# rs2796441JG# TLE1# 1.07#
2# rs243088JT# BCL11A# 1.07# 9# rs16927668JT# PTPRD# 1.04#
2# rs13389219JC# GRB14# 1.07# 10# rs11257655JT# CDC123/CAMK1D# 1.07#
2# rs2943640JC# IRS1# 1.10# 10# rs7903146JT# TCF7L2# 1.39#
2# rs7569522JA# RBMS1# 1.05# 10# rs1111875JC# HHEX/IDE# 1.11#
2# rs780094JC# GCKR# 1.06# 10# rs12571751JA# ZMIZ1#or#PPIF# 1.08#
3# rs11717195JT# ADCY5# 1.11# 10# rs12242953JG# VPS26A# 1.07#
3# rs1496653JA# UBE2E2# 1.09# 11# rs10830963JG# MTNR1B# 1.10#
3# rs4402960JT# IGF2BP2# 1.13# 11# rs1552224JA# ARAP1#(CENTD2)# 1.11#
3# rs1801282JC# PPARG# 1.13# 11# rs163184JG# KCNQ1# 1.09#
3# rs6795735JC# ADAMTS9# 1.08# 11# rs5215JC# KCNJ11# 1.07#
3# rs12497268JG# PSMD6# 1.03# 11# rs2334499JT# DUSP8#or#HCCA2#(YY1AP1)# 1.04#
3# rs17301514JA# ST64GAL1# 1.05# 12# rs7955901JC# TSPAN8/LGR5# 1.07#
4# rs6819243JT# MAEA# 1.07# 12# rs12427353JG# HNF1A#(TCF1)# 1.08#
4# rs4458523JG# WFS1# 1.10# 12# rs2261181JT# HMGA2# 1.13#
5# rs6878122JG# ZBED3#or#PDE8B# 1.10# 12# rs10842994JC# KLHDC5#or#PPFIBP1# 1.10#
5# rs459193JG# ANKRD55# 1.08# 13# rs1359790JG# SPRY2# 1.08#
6# rs7756992JG# CDKAL1# 1.17# 15# rs4502156JT# C2CD4A#or#VPS13C# 1.06#
6# rs3734621JC# KCNK16# 1.07# 15# rs11634397JG# ZFAND6# 1.05#
6# rs4299828JA# ZFAND3# 1.04# 15# rs12899811JG# PRC1# 1.08#
7# rs17168486JT# DGKB# 1.11# 15# rs2007084JG# AP3S2# 1.02#
7# rs10278336JA# GCK## 1.07# 15# rs7177055JA# HMG20A# 1.08#
7# rs849135JG# JAZF1# 1.11# 16# rs9936385JC# FTO# 1.13#
7# rs17867832JT# GCC1#or#PAXP4# 1.09# 16# rs7202877JT# BCAR1# 1.12#
7# rs13233731JG# KLF14# 1.05# 17# rs2447090JA# SRR# 1.04#
8# rs3802177JG# SLC30A8# 1.14# 18# rs12970134JA# MC4R# 1.08#
8# rs7845219JT# TP53INP1# 1.06# 19# rs10401969JC# CILP2# 1.13#
8# rs516946JC# ANK1# 1.09# 19# rs8182584JT# PEPD# 1.04#
9# rs10811661JT# CDKN2A/B# 1.18# 20# rs4812829JA# HNF4A# 1.06#
#
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Supplemental*Table*2*–*Outline*of*models*applied*in*the*association*analysis*of*Genetic*
Risk*Scores*(GRS)*with*subclinical*atherosclerosis*traits,*plus*covariates.*
*
BASIC*MODEL*
#
GRS,#sex#
#
#
FULL*MODEL* GRS,#sex#
#
Age#
BMI#
Waist#circumference#
Systolic#blood#pressure#(SBP)*#
#
Fasting#insulin#
Fasting#glucose#
Triglycerides#
HDLJCholesterol#
LDLJCholesterol#
#
Family#history#of#T2D#
Family#history#of#CVD#
#
Smoking#status#
Physical#activity#
#
Diabetes#medication#
Hypertension#medication#
LipidJlowering#medication#
#
#
BMI,#body#mass#index;#T2D,#type#2#diabetes;#CVD,#cardiovascular#disease;#ABI,#ankleJbrachial#index.#
*NOTE:#SBP#excluded#for#ABI#since#ABI#is#calculated#from#SBPs#at#ankle#and#arm.#
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Supplemental*Table*3*–*Subclinical*atherosclerosis*measures,*anthropometric*and*clinical*characteristics*in*FHS*and*CARDIA*cohorts.!
! ! !
! FHS! CARDIA!
! * * * *
! Exam%6% Exam%7% Exam%year%20% Exam%year%25%
! * * * *
Ethnicity! European*Americans* African*Americans* European*Americans* African*Americans* European*Americans*
N!(male!%)! 2459!(44.8%)! 1111!(44.8%)! 816!(38.6%)! 1635!(45.9!%)! 811!(38.8%)! 1621!(45.9!%)!
Age!(yr)! 57.9!±!9.6! 58.9!±!8.9! 44.4!±!3.8! 45.5!±!3.3! 49.4!±!3.8! 50.6!±!3.3!
BMI!(kg/m2)! 27.6!±!4.9! 28.1!±!4.9! 31.7!±!7.6! 27.9!±!6.7! 32.2!±!7.8! 28.2!±!6.2!
Waist!circumference!(cm)! 96.5!±!12.7! 96.5!±!12.7! 94.7!±!15.7! 89.8!±!15.1! 97.1!±!15.8! 91.6!±!15.6!
Systolic!blood!pressure!(mmHg)! 127.1!±!18.3! 124.9!±!17.7! 119.1!±!15.5! 112.2!±!12.5! 122.2!±!14.5! 114.5!±!13.7!
Fasting!glucose!(mg/dL)! 101.3!±!22.9! 99.9!±!18.2! 102.3!±!30.2! 97.8!±!21.2! 102.1!±!34.6! 96.7!±!20.4!
Fasting!insulin!(pmol/L)! P! 14.3!±!8.6! 17.1!±!12.2! 13.5!±!9.1! 13.39!±!14.1! 9.6!±!7.3!
Triglycerides!(mg/dL)! 136.1!±!88.2! 132.6!±!86.5! 96.4!±!58.4! 116.9!±!82.4! 101.4!±!67.1! 120.0!±!86.3!
HDLPcholesterol!(mg/dL)! 51.9!±!16.1! 53.9!±!15.9! 54.1!±!16.3! 54.4!±!17.2! 57.7!±!17.3! 58.7!±!18.5!
LDLPcholesterol!(mg/dL)! 127.4!±!32.9! 121.4!±!31.3! 110.4!±!33.6! 110.3!±!30.5! 109.2!±!33.9! 113.4!±!30.9!
Parental!history!of!diabetes!(%)! 19.8! 19.8! 17.9! 9.5! 17.6! 9.4!
Parental!history!of!CVD!(%)! 43.2! 41.9! 39.8! 41.3! 39.9! 41.2!
Diabetes!(%)! 7.1! 6.3! 10.9! 3.4! 13.3! 6.5!
Smokers!(never/former/current!P!%)! 35.8/48.9/15.2*! 39.5/50.7/9.8*! 59.9/40.1†! 46.1/53.9†! 62.2/37.9†! 50.7/49.3†!
Physical!activity!! P! P! 287.5±285.4‡! 370.3±260.8‡! 264.4±257.5‡! 388.0±280.9‡!
Genetic!Risk!Score! 66.7!±!5.3! 66.7!±!5.2! 69.2!±!4.5! 66.4!±!5.2! 69.2!±!4.5! 66.4!±!5.2!
! ! ! ! !
Comorbidity!status! ! ! ! !
! ! ! ! !
Diabetes!medication!(%)! 3.3! 2.9! 7.9! 3.4! 10.7! 4.6!
Hypertension!medication!(%)! 23.4! 24.8! 23.1! 10.2! 41.8! 31.8!
LipidPlowering!medication!(%)! 9.8! 13.9! P! P! P! P!
! % % % %
Subclinical!atherosclerosis!traits! % % % %
! ! ! ! !
AACS!(Agatston!unit)! P! 1458.6!±!2332.3! P! P! P! P!
CACS!(Agatston!unit)! P! 229.8!±!550.8! P! P! 31.7!±!154.6!(n=586)! 49.2!±!252.1!(n=1267)!
CCAPIMT!(mm)!! 0.5!±!0.4!(n=2340)! P! 0.7!±!0.1!(n=617)! 0.7!±!0.1!(n=1379)! P! P!
ICAPIMT!(mm)!! 0.8!±!1.9!(n=2035)! P! 0.6!±!0.2!(n=562)! 0.6!±!0.2!(n=1332)! P! P!
ABI! 1.1!±!0.1!(n=2822)! P! P! P! P!
! ! ! ! !
!
Data! expressed! as!mean±standard!deviation,! if! not! otherwise! indicated.!AACS,! abdominal! aorta! calcium! score;! CACS,! coronary! artery! calcium! score;! CCA,! common! carotid! artery;! ICA,! internal!
carotid!artery;!IMT,!intimaPmedia!thickness;!ABI,!anklePbrachial!index.!*Smoking!status!categorized!as!never/former/current!in!FHS.!†Smoking!status!categorized!as!never/ever!in!CARDIA.!‡Physical!
activity!is!expressed!as!Total!Intensity!Score,!according!to!the!CARDIA!Physical!Activity!History!Questionnaire!(Pereira!MA!et%al.;!PMID:!9243481).!!
!
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Supplemental*Table*4*–*Subclinical*atherosclerosis*measures,*anthropometric*and*clinical*characteristics*in*MESA*and*GENOA*cohorts.!
! ! !
! MESA! GENOA*
! * ! ! ! * *
! * * * * *
! * * * * * *
Ethnicity! European*Americans* Asian*Americans* African*Americans* Hispanic*Americans* European*Americans* African*Americans||*
N!(male!%)! 2526!(47.7%)! 773!(49.2%)! 1611!(46.1%)! 1446!(48.3%)! 969!(40.9%)! 535!(25.8%)!
Age!(yr)! 62.7!±!10.2! 62.4!±!10.4! 62.3!±!10.1! 61.4!±!10.3! 58.9!±!9.5! 68.5!±!7.7!
BMI!(kg/m2)! 27.7!±!5.1! 23.9!±!3.3! 30.2!±!5.9! 29.5!±!5.2! 30.7!±!6.3! 32.7!±!7.2!
Waist!circumference!(cm)! 97.9!±!14.5! 87.1!±!9.8! 101.3!±!14.7! 100.7!±!13.1! 100.3!±!16.2! 101.1!±!15.4!
Systolic!blood!pressure!(mmHg)! 123.5!±!20.5! 124.6!±!21.7! 131.8!±!21.8! 126.8!±!21.9! 131.4!±!16.8! 137.5!±!21.0!
Fasting!glucose!(mg/dL)! 91.3!±!21.6! 99.2!±!28.6! 100.3!±!32.7! 103.9!±!39.4! 104.6!±!24.5! 111.6!±!37.7!
Fasting!insulin!(pmol/L)! 9.1!±!5.6! 9.6!±!12.5! 11.5!±!27.5! 11.8!±!15.7! 54.2!±!40.3! 80.6!±!87.5!
Triglycerides!(mg/dL)! 133!±!90.1! 143.1!±!85.7! 105.2!±!70.5! 158.4!±!101.8! 159.0!±!96.9! 101.0!±!63.3!
HDLPcholesterol!(mg/dL)! 52.4!±!15.8! 49.3!±!12.4! 52.3!±!15.2! 47.5!±!13.1! 52.4!±!15.6! 57.1!±!16.5!
LDLPcholesterol!(mg/dL)! 117.1!±!30.3! 115.1!±!28.8! 116.7!±!33.3! 119.9!±!32.9! 122.7!±!32.1! 114.6!±!35.3!
Parental!history!of!diabetes!(%)! P! P! P! P! 29.4! 40.9!
Parental!history!of!CVD!(%)! 44.6/33.2/2.8*!! 14.5/23.3/1.2*! 31.9/31/7*! 31.2/23.8/3.2*! 57.5†!! 56.1†!
Diabetes!(%)! 5.9! 13.5! 17.4! 17.8! 13.5! 35.5!
Smokers!(never/former/current!P!%)! 33.1/66.9‡! 69.6/30.4‡! 26.6/73.4‡! 40.7/59.3‡! 52.5/37.3/10.2! !60.4/31.4/8.2!
Regular!physical!activity!(daily!hours)! 12.8!±!4.9! 9.9!±!4.4! 14.4!±!7.1! 11.6!±!5.9! 3.7!±!2.5§! 1.0!±!1.8§!
Genetic!Risk!Score! 63.9!±!4.7! 61.5!±!4.2! 56.5!±!4.7! 62.7!±!4.8! 64.2!±!4.9! 57.0!±!3.9!
! ! ! ! ! ! !
Comorbidity!status! ! ! ! ! ! !
! ! ! ! ! ! !
Diabetes!medication!(%)! 4.6! 9.2! 13.6! 15.8! 8.9! 32.0!
Hypertension!medication!(%)! 33.3! 29.1! 50.3! 32.9! 68.4! 80.8!
LipidPlowering!medication!(%)! 18.3! 14.1! 15.8! 13.3! 27.0! 40.9!
! % % % % % %
Subclinical!atherosclerosis!traits! % % % % % %
! ! ! ! ! ! !
AACS!(Agatston!unit)! 1668.4!±!2581.4!(n=760)! 1044.7!±!2015.4!(n=247)! 887.2!±!1737.7!(n=343)! 1044.6!±!1898.4!(n=496)! P! P!
CACS!(Agatston!unit)! 338.6!±!577.2!(n=1433)! 205.8!±!374.3!(n=392)! 294.0!±!582.8!(n=714)! 281.4!±!567.2!(n=659)! 201.6!±!467.2! 236.3!±!583.0!
CCAPIMT!(mm)!! 0.9!±!0.2!(n=2501)! 0.8!±!0.2!(n=770)! 0.9!±!0.2!(n=1573)! 0.9!±!0.2!(n=1431)! P! P!
ICAPIMT!(mm)!! 1.1!±!0.6!(n=2475)! 0.9!±!0.5!(n=766)! 1.1!±!0.6!(n=1547)! 1.0!±!0.6!(n=1399)! P! P!
ABI! 1.1!±!0.1!(n=2494)! 1.1!±!0.1!(n=768)! 1.1!±!0.1!(n=1432)! 1.3!±!0.1!(n=1430)! P! P!
! ! ! ! ! ! !
!
Data! expressed!as!mean±standard!error,! if! not!otherwise! indicated.!AACS,! abdominal! aorta! calcium! score;! CACS,! coronary! artery! calcium! score;! CCA,! common! carotid! artery;! ICA,! internal! carotid! artery;! IMT,! intimaPmedia!
thickness;!ABI,!anklePbrachial!index.!*CVD!is!categorized!in!MESA!as!myocardial!infarction/stroke/amputation!not!due!to!injury.!†Expressed!as!parental!history!of!coronary!heart!disease!in!GENOA.!‡Smoking!status!categorized!as!
never/ever!in!MESA.!**Smoking!status!categorized!as!never/former/current!in!GENOA.!§Physical!activity!categorized!as!moderate!or!heavy.!||African!Americans!in!GENOA!had!an!available!genetic!risk!score!limited!to!55!of!62!T2D!
SNPs.!
!
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Supplemental* Table* 5* –*Association* between*prevalent* subclinical* atherosclerosis*measures* and* a*
T2D*genotype*risk*score*(GRS)*comprised*of*20*tag*SNPs*mostly*linked*with*betaRcell*function*(GRSβ)*
in*linear*regression*models*of*FHS*and*CARDIA*cohorts.!
! ! !
! FHS! CARDIA!
*
*
* European*Americans* African*Americans* European*Americans*
* * * * *
Basic*Model* Beta±SE% P% Beta±SE% P% Beta±SE% P%
! * * * *
CACS* P0.023±0.05! 0.64! P0.011±0.03! 0.71! 0.005±0.02! 0.76!
AACS* P0.072±0.06! 0.23! P! P! P! P!
ICARIMT* P0.016±0.01! 0.01! P0.001±0.00! 0.55! 0.001±0.00! 0.31!
CCARIMT* P0.002±0.00! 0.41! P0.001±0.00! 0.60! 0.000±0.00! 0.69!
ABI* P9.33E+08±0.00! 0.94! P! P! P! P!
* ! ! ! !
Full*Model* % % % % % %
! ! ! ! !
CACS* P0.021±0.05! 0.69! P0.027±0.03! 0.36! 0.001±0.02! 0.95!
AACS* P0.012±0.06! 0.85! P! P! P! P!
ICARIMT* P0.018±0.01! 0.007* P0.001±0.00! 0.68! 0.001±0.00! 0.15!
CCARIMT! P0.004±0.00* 0.15! P0.001±0.00! 0.49! 0.001±0.00! 0.21!
ABI* 0.001±0.00! 0.46! P! P! P! P!
! ! ! ! !
AACS,!abdominal!aorta! calcium!score;!CACS,! coronary!artery! calcium!score;!CCA,! common!carotid!artery;! ICA,! internal! carotid!artery;! IMT,!
intimaPmedia!thickness;!ABI,!anklePbrachial!index.!Data!expressed!as!mean±standard!error.!
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Supplemental* Table* 6* –*Association* between*prevalent* subclinical* atherosclerosis*measures* and* a*
T2D*genotype*risk*score*(GRS)*comprised*of*10*tag*SNPs*mostly*linked*with*insulin*resistance*(GRSIR)*
in*linear*regression*models*of*FHS*and*CARDIA*cohorts.!
! ! !
! FHS! CARDIA!
*
*
* European*Americans* African*Americans* European*Americans*
* * * * *
Basic*Model* Beta±SE% P% Beta±SE% P% Beta±SE% P%
! * * * *
CACS* P0.004±0.07! 0.95! P0.011±0.04! 0.98! 0.041±0.03! 0.11!
AACS* 0.112±0.08! 0.17! P! P! P! P!
ICARIMT* P0.003±0.01! 0.77! 0.000±0.00! 0.93! P0.001±0.00! 0.71!
CCARIMT* P0.004±0.00! 0.29! 0.001±0.00! 0.46! P0.000±0.00! 0.77!
ABI* P7.74P06±0.00! 0.99! P! P! P! P!
* ! ! ! !
Full*Model* % % % % % %
! ! ! ! !
CACS* 0.036±0.08! 0.65! 0.005±0.04! 0.89! 0.025±0.03! 0.32!
AACS* 0.056±0.09! 0.57! P! P! P! P!
ICARIMT* P0.005±0.01! 0.65! 0.001±0.00! 0.84! P0.000±0.00! 0.83!
CCARIMT! P0.009±0.00* 0.01! 0.001±0.00! 0.58! P0.001±0.00! 0.63!
ABI* 0.001±0.00! 0.56! P! P! P! P!
! ! ! ! !
AACS,!abdominal!aorta!calcium!score;!CACS,!coronary!artery!calcium!score;!CCA,!common!carotid!artery;! ICA,! internal!carotid!artery;! IMT,!
intimaPmedia!thickness;!ABI,!anklePbrachial!index.!Data!expressed!as!mean±standard!error.*
!
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Supplemental*Figure*1*–*Distribution*of*the*total*sum*of*risk*alleles*comprised*in*the*T2D*GRS62*in*GENOA*(panel*A*and*B)*and*MESA*
cohorts*(panels*C*to*F),*stratified*by*ethnicity.*
 11 
 
 
Supplemental*Figure*2*–*Distribution*of*the*total*sum*of*risk*alleles*comprised*in*the*T2D*GRS62,*GRSβ*and*GRSIR*in*FHS*(panel*A,*B,*C,*
respectively)*and*in*CARDIA*cohorts*(panel*D*to*I),*stratified*by*ethnicity.*
 12 
Supplemental*References*
 
1.# Morris#AP,#Voight#BF,#Teslovich#TM,#Ferreira#T,#Segre#AV,#Steinthorsdottir#V,#et#al.#Large<
scale# association# analysis# provides# insights# into# the# genetic# architecture# and#
pathophysiology#of#type#2#diabetes.#Nat$Genet.#2012;44:981<990.#
#
2.# Vassy# JL,# Hivert#MF,# Porneala# B,# Dauriz#M,# Florez# JC,# Dupuis# J,# et# al.# Polygenic# type# 2#
diabetes#prediction#at# the# limit#of# common#variant#detection.#Diabetes.#2014;63:2172<
2182.#
#
3.# Dimas#AS,# Lagou#V,# Barker# A,# Knowles# JW,#Magi# R,# Hivert#MF,# et# al.# Impact# of# type# 2#
diabetes# susceptibility# variants# on# quantitative# glycemic# traits# reveals# mechanistic#
heterogeneity.#Diabetes.#2014;63(6):2158<2171.#
#
4.# Scott# RA,# Lagou# V,# Welch# RP,# Wheeler# E,# Montasser# ME,# Luan# J,# et# al.# Large<scale#
association#analyses#identify#new#loci#influencing#glycemic#traits#and#provide#insight#into#
the#underlying#biological#pathways.#Nat$Genet.#2012;44:991<1005.#
#
5.# Manning#AK,#Hivert#MF,#Scott#RA,#Grimsby#JL,#Bouatia<Naji#N,#Chen#H,#et#al.#A#genome<
wide# approach# accounting# for# body#mass# index# identifies# genetic# variants# influencing#
fasting#glycemic#traits#and#insulin#resistance.#Nat$Genet.#2012;44:659<669.#
#
6.# Lindgren#CM,#Heid#IM,#Randall#JC,#Lamina#C,#Steinthorsdottir#V,#Qi#L,#et#al.#Genome<wide#
association# scan# meta<analysis# identifies# three# Loci# influencing# adiposity# and# fat#
distribution.#PLoS$Genet.#2009;5(6):e1000508.#
#
7.# Lettre# G,# Palmer# CD,# Young# T,# Ejebe# KG,# Allayee# H,# Benjamin# EJ,# et# al.# Genome<wide#
association# study# of# coronary# heart# disease# and# its# risk# factors# in# 8,090# African#
Americans:#the#NHLBI#CARe#Project.#PLoS$Genet.#2011;7(2):e1001300.#
#
8.# Li#YA#GR.#Mach#1.0:#Rapid#haplotype#reconstruction#and#missing#genotype#inference.#Am$
J$Hum$Genet$2006;S79:2290.#
#
9.# Gabriel#SB,#Schaffner#SF,#Nguyen#H,#Moore#JM,#Roy#J,#Blumenstiel#B,#et#al.#The#structure#
of#haplotype#blocks#in#the#human#genome.#Science.#2002;296:2225<2229.#
 
